Business Wire

CORRECTING and REPLACING GRAPHIC: Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Shown in a Recent Study to Have Beneficial Effects on Human Health and Well-being

Share

Please replace the graphic with the accompanying corrected graphic on the release issued May 27, 2019 at 9am BST.
The release reads:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190527005028/en/

Seoul Semiconductor's SunLike Series Natural Spectrum LEDs (Graphic: Business Wire)

Seoul Semiconductor's SunLike Series Natural Spectrum LEDs (Graphic: Business Wire)

SEOUL SEMICONDUCTOR’S SUNLIKE SERIES NATURAL SPECTRUM LEDS SHOWN IN A RECENT STUDY TO HAVE BENEFICIAL EFFECTS ON HUMAN HEALTH AND WELL-BEING

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced the results of a recent study conducted by Dr. Octavio L. Perez, adjunct researcher in Integrative Lighting at Mount Sinai Hospital in NYC, NY, USA on the non-visual melanopic stimulus of LED sources. The study showed that the company’s SunLike Series natural spectrum LEDs provide up to 21% more melanopic stimulus than conventional LEDs at 4000K, and the same melanopic stimulus as daylight at 6500K (D65).

In addition to the visual effects of light and lighting on people, such as visual acuity and color fidelity, there are also non-visual effects. These non-visual effects can affect human health and well-being in aspects related to sleep, awakeness, alertness, circadian rhythmicity, circadian disruption, performance, and mood. Recent building standards, such as the ‘WELL Building Standard,’ assess these non-visual effects of lighting in buildings in terms of the ‘melanopic stimulus,’ not just in terms of conventional photometry and colorimetry.

The recent study evaluated the M-EDI (CIE DIS S026/E:2018 Melanopic Equivalent Daylight Illuminance) of different light sources at different correlated color temperatures (CCT in K). M-EDI is the only metric compliant with the International System of Units (IS) to evaluate the non-visual stimulus of light and lighting, based on the CIE (the International Commission on Illumination) D65 standard daylight illuminant. The preliminary results indicate that the SunLike Series natural spectrum LEDs provide more melanopic stimulus, at any given CCT, than any other LED light source at the same photopic illuminance (in lux) – up to 21% more M-EDI stimulus compared to a conventional 4000K CRI80 LED (4000K being the prevalent CCT in office and school environments).

A typical 4000K CRI80 LED provides 59.30 M-EDI lux for every 100 photopic lux, and a 4000K SunLike LED provides 71.94 M-EDI lux at the same photopic illuminance level. At 6500K, the SunLike LED delivers 99.95% of the M-EDI melanopic stimulus provided by the CIE D65 daylight standard illuminant at the same photopic illuminance. It means that at 6500K, the SunLike Series LEDs provide the same natural melanopic stimulus as daylight (D65).

The reason for this is that the SunLike Series natural spectrum LEDs have a continuous spectral power distribution (SPD) emission that mimics sunlight spectrum at different CCT, in the visual region not including UV and IR. Conventional LED light sources have a peak at 450nm, followed by a valley at the peak of the melanopic efficiency curve, around 480nm. This peak at 450nm for conventional LEDs may also produce non-desired effects on eye health. The melanopic stimulus of the 6500K SunLike LEDs match the shape of the melanopic stimulus provided by D65, avoiding potential blue light peak and ethical issues.

Human centric lighting solutions go beyond the prevalent visual metrics of photometry colorimetry and conventional lighting design. The SunLike Series natural spectrum LEDs offer better visual appearance and color fidelity (CRI95+), and are specifically designed and engineered to provide more benefits and energy for human health and well-being than any other LED in the marketplace. SunLike Series LEDs are the light source of choice for integrative lighting solutions.

Seoul Semiconductor’s SunLike Series natural spectrum LEDs are the world’s first LEDs to produce light that closely matches the spectrum of natural sunlight. It has also achieved the highest level of eye safety certification from the International Commission on Illumination as an RG-1 level light source with no photo-biological risks.

SunLike Series natural spectrum LEDs were co-developed through the combination of Seoul Semiconductor’s optical semiconductor technology and Toshiba Materials’ TRI-R technology, which defines its original concept as “the light closest to the sun for human well-being.” TRI-R technology enables the spectrum of natural sunlight to be reproduced by a white LED light source. TRI-R is a registered trademark of Toshiba Material Co., Ltd.

The left figure is how the melanopic stimulus of commercial LEDs increases and the right figure shows the same results by family of LEDs. SunLike LEDs provide more melanopic stimulus than the other LEDs (study under publication).

# # #

About Dr. Octavio L. Perez
Dr. Octavio L. Perez is a passionate professional and scholar who contributes to exploring, developing and bringing to the real world the benefits of light and lighting for human wellbeing and wellness, and ultimately health, integrating in this vision the traditional visual and aesthetical principles of lighting, altogether with energy savings and sustainability values. He works internationally as an independent consultant, focused in human centric lighting (HCL), more precisely “affective lighting”. He is also an adjunct researcher at Mount Sinai Hospital in NYC, where he completed his doctoral research with funding from NIH (National Institutes of Health).

About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en.

Contact information

Seoul Semiconductor Inc.
Jeonghee Kim
Tel: +82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump5.6.2020 13:00:00 CESTPress release

Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start an early feasibility study with a first-in-human trial of the 9 French (Fr) Impella ECP™ heart pump. Impella ECP, which stands for expandable cardiac power, will be studied in high-risk percutaneous coronary intervention (PCI) patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005049/en/ FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump Impella ECP is the world’s smallest heart pump. It achieves peak flows greater than 3.5 L/min and is delivered though a slender-profile sheath. It is un-sheathed in the descending aorta and expands to approximately 18 Fr. Using a specially designed pigtail, it crosses the aortic valve without a wire, and pumps from inside the ventricle. When the procedure is complete, the pump is

Next generation of DataOps, provided by Datalytyx, now available through Snowflake Partner Connect Program!5.6.2020 11:10:00 CESTPress release

Datalytyx today announced an expanded partnership with Snowflake, the Cloud Data Platform, that enables the next generation Datalytyx DataOps for Snowflake platform to be deployed for a 2 week trial on Snowflake. Customers can orchestrate the ingestion of data from many on-premise and cloud platforms via 3rd party data tools, model data easily, automatically test those models as part of their pipelines, launch AI/ML models and enable the consumption of data to deliver immediate stakeholder value. As a great example, in the midst of the Coronavirus pandemic, BOC, the UK market-leading gas supply company for delivery of healthcare oxygen, has faced unprecedented demand, from equipping Nightingale hospitals to delivering O2 cylinders in homes. Datalytyx have deployed their DataOps for Snowflake platform to help BOC manage their cylinder stock and logistics data, for all types of gases, to increase production efficiency and provide best-in-class customer service. “Datalytyx said they could

Pegasus Development AG: Green Light for Multiple Production Sites Worldwide5.6.2020 09:27:00 CESTPress release

Announcement: Expansion of the Pegastril-Nuevo production facility Under the leadership of board member Roberto Spano, the management of Pegasus Development AG has decided to further expand Pegastril-Nuevo production facilities. New production facilities will be set up at several locations across the world and the site in Turkey is being expanded. These investments will also create new jobs. The takeover and expansion of the following production facilities are planned in all 20 countries of Latin America, as well as France, Spain, Portugal, Greece, Cyprus, Nigeria, Ethiopia, Uganda, Tanzania, Mozambique, Angola, Mauritius, Guinea-Bissau, Cape Verde, São Tome, and Mongolia. The demand for disinfectants has skyrocketed as a result of the coronavirus. Especially high revenues are expected from products which are based on vegetable surfactants and are alcohol-free, such as Nuevo. This was the decisive factor in the management's decision to further expand the quantity and range of Nuevo pro

In COVID-19, Pudu Robotics Provides Non-contact Delivery Service in Hundreds of Hospitals Worldwide5.6.2020 09:00:00 CESTPress release

During COVID-19, hundreds of Pudu Robotics’ robot Pudubot is offering delivery service in hospitals worldwide. This non-contact delivery service by Pudubot helps avoid the spread of virus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005095/en/ (Photo: Business Wire) After the outbreak of COVID-19, the pandemic with the characteristic of human-to-human transmission, a large number of hospitals and restaurants are seeking help from Pudu Robotics out of an urgent need for non-contact delivery. Pudu Robotics responded positively by devoting robots to several hospitals in Seoul, South Korea, Beijing, China, Wuhan, China and so on. Because Pudu Robotics’ robots are fully automatic, they can achieve the delivery process all by themselves, which reduces contact between people and effectively prevents the spread of the virus. Pudubot is equipped with multi-sensor and positioning and navigation technology. With large-capacity

IDEMIA and BBVA Partner to Launch Spain’s First Payment Card Made of Recycled PVC5.6.2020 09:00:00 CESTPress release

IDEMIA, the global leader in Augmented Identity, is supplying the very first cards made out of recycled plastics in Spain to BBVA. The bank will first distribute the cards to their Spanish customers with a BBVA Youth Account in June 2020. This new payment card is a strong commitment from BBVA to contributing to the United Nations Sustainable Development Goals for the fight against climate change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005037/en/ (Graphic: Business Wire) Each year, approximately 6 billion plastic payment cards are produced according to the 2018 Nilson Report1. In the context of the United Nations Sustainable Development Goals and the Paris Agreement, IDEMIA’s cutting-edge technology has been selected by BBVA, one of the largest banks in Spain, to migrate part of its existing first-use PVC cards to innovative recycled PVC cards. By the end of the year BBVA will enable more than half a million Spa

EIT Digital: Strengthening European Digital Infrastructure and Data Sovereignty5.6.2020 06:00:00 CESTPress release

Recent discussions around access to 5G technology and COVID-19 contact tracing apps highlight the need for European digital sovereignty. In its latest policy perspective report on ‘European Digital Infrastructure- and Data Sovereignty’, EIT Digital offers a concrete scenario-based framework for digital policy development. The study provides an overview of policy motivations, trends, instruments, and the roles of various actors in defining the perception of and perspectives for Europe’s digital sovereignty. “What becomes clear is that we need coordinated action between the policy shapers at European and national levels and the makers from business and industry to create a sovereign European digital reality. Key are policies that enhance innovation and respect European values and rights while creating equal economic opportunity for all actors,” says EIT Digital CEO Willem Jonker. EIT Digital collaborated with the Digital Enlightenment Forum to execute the report. The study supports the d